Cargando…

Correction: The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity

Detalles Bibliográficos
Autores principales:	DeGrasse, David C, Black, Shaun D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268559/ https://www.ncbi.nlm.nih.gov/pubmed/37325688 http://dx.doi.org/10.7759/cureus.c122

Ejemplares similares

The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity
por: DeGrasse, David C, et al.
Publicado: (2023)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

Immune Evasion of SARS-CoV-2 Omicron Subvariants
por: Ke, Hanzhong, et al.
Publicado: (2022)

Reinfections with Different SARS-CoV-2 Omicron Subvariants, France
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Emergence of the Omicron SARS-CoV-2 subvariants during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the host
por: Tang, Haijun, et al.
Publicado: (2023)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
por: Wang, Qian, et al.
Publicado: (2022)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
por: Moriyama, Miyu, et al.
Publicado: (2023)

Comparison of the replication and neutralization of different SARS‐CoV‐2 Omicron subvariants in vitro
por: Zhang, Yaqing, et al.
Publicado: (2023)

Effects of tea, catechins and catechin derivatives on Omicron subvariants of SARS-CoV-2
por: Shin-Ya, Masaharu, et al.
Publicado: (2023)

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
por: Chiang, Hsiao-Ling, et al.
Publicado: (2023)

Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients
por: Deng, Haohui, et al.
Publicado: (2023)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
por: Tamura, Tomokazu, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England
por: Strasser, Zachary H., et al.
Publicado: (2022)

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
por: Cho, Junhyung, et al.
Publicado: (2023)

SARS-CoV-2 Omicron subvariant spike N405 unlikely to rapidly deamidate
por: Beaudoin, Christopher A., et al.
Publicado: (2023)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan
por: Liu, Li-Teh, et al.
Publicado: (2023)

SARS-CoV-2/Omicron subvariants: global outbreak upsurge and expected upcoming threats
por: Malik, Sumira, et al.
Publicado: (2023)

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
por: Wang, Qian, et al.
Publicado: (2023)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants
por: Desautels, Thomas A., et al.
Publicado: (2023)

Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants
por: Mäkelä, Anna R., et al.
Publicado: (2023)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants
por: Alcantara, Mellissa C., et al.
Publicado: (2023)

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
por: Moriyama, Saya, et al.
Publicado: (2023)

Comparative Computational Analysis of Spike Protein Structural Stability in SARS-CoV-2 Omicron Subvariants
por: Balupuri, Anand, et al.
Publicado: (2023)

SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread
por: Wang, Xinling, et al.
Publicado: (2023)

The emergence of new SARS-CoV-2 omicron subvariants introduces uncertainty about the end of the COVID-19 pandemic
por: da Silva, Severino Jefferson Ribeiro
Publicado: (2022)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children
por: Li, Xiaohe, et al.
Publicado: (2022)

Global Distribution, Dispersal Patterns, and Trend of Several Omicron Subvariants of SARS-CoV-2 across the Globe
por: Kopsidas, Ioannis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_02fvibdc7t3lrrtmb2gd0s7d6v